# Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

> **NCT00264615** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 45 (—)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** lamotrigine extended-release

## Key facts

- **NCT ID:** NCT00264615
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 45 (—)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264615, "Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00264615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*